State Of Incorporation UT Jurisdiction Of Incorporation USA Company Officers Richard Gabriel, President, CEO Monica Tamborini, CFO
CIK 0001127354 Estimated Market Cap 4,477,541.312 as of Oct 16, 2007 Outstanding Shares 552,782,878 as of Apr 27, 2007 Number of Share Holders of Record 1,034 as of Mar 15, 2007 Current Capital Change shs decreased by 1 for 20 split Pay Date: Jul 12, 2005 Company Notes Note=9-30-04 company is in the development stage Formerly=Catalyst Communications Inc. until 7-00 Formerly=Homestyle Harmony, Inc. until 12-96 Security Notes Capital Change=shs decreased by 1 for 10 split. Effective date=9-16-96 Div. One sh Global Resources Group, Inc. Com for each 10 shs Com held. Ex-date=5-21-98 Rec date=3-9-98 Pay date=5-28-98 New Issue=1-84 1,500,000 shs at 1 Cent (best efforts - 750,000 min.) in the state of Utah only by the company Transfer Agent Standard Registrar and Transfer Co., Inc., 12528 South 1840 E. Draper, UT 84020
Pink Sheets News Service No News Releases exist.
DNAPrint Genomics to Present at Valuerich Small-Cap Financial Expo
SARASOTA, FL, Oct 10, 2007 (MARKET WIRE via COMTEX) -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that Chief Executive Officer and President Richard Gabriel will present an overview of the Company to analysts at the ValueRich Small-Cap Financial Expo on Thursday, Oct. 18, 2007 at 1:35 p.m. eastern time. The expo will be held at the W New York Hotel, 541 Lexington Avenue in New York City. During the 20-minute presentation, Mr. Gabriel will provide an overview of the Company and discuss its goals and outlook for the future. A webcast of the presentation will be available for 180 days after the show at http://www.ivaluerich.com/expo or on the Company's website at www.dnaprint.com.
About DNAPrint Genomics, Inc.
DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.
Company Contact: Richard Gabriel CEO and President 941 366-3400 -or- Ron Stabiner The Wall Street Group, Inc. 212-888-4848
SOURCE: DNAPrint Genomics, Inc.
Copyright 2007 Market Wire, All rights reserved.
-0-
SUBJECT CODE: Pharmaceuticals and Biotech:Biotech Pharmaceuticals and Biotech:Drugs Pharmaceuticals and Biotech:Equipment and Supplies Pharmaceuticals and Biotech:Trials
IMAKEMONEY
posted
BOUNCE!!!!!!!!!!
IMAKEMONEY
posted
YEP! LOL
IMAKEMONEY
posted
LETS DO IT AGIAN!
Yankee
posted
Its been years for this one. I got friends that bought at .30 . They are still waiting.
posted